[Asia Economy Reporter Lee Jung-yoon] SK Bioscience announced on the 19th that it has signed a contract with Novavax to produce prefilled syringe (PFS) formulations of the COVID-19 vaccine worth 39.5 billion KRW.
This amount corresponds to 4.25% of last year's sales, and the contract period is from the day before until December 31 of this year.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
